Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) Cyclically Adjusted Revenue per Share: ¥3.46 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603896 Zhejiang Shouxiangu Pharmaceutical Co Ltd SHSE:603896
58 GF Score
Price ¥15.14
GF Value ¥23.29
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Zhejiang Shouxiangu Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Zhejiang Shouxiangu Pharmaceutical Co SHSE:603896 -2.07% 58 Cyclically Adjusted Revenue per Share is ¥3.46 as of Mar. 2026. GuruFocus rates SHSE:603896 with a GF Score™ of 58/100 and a GF Value™ of ¥23.29 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zhejiang Shouxiangu Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.835. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥3.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zhejiang Shouxiangu Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-16), Zhejiang Shouxiangu Pharmaceutical Co's current stock price is ¥15.14. Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥3.46. Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 4.38.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Shouxiangu Pharmaceutical Co was 6.79. The lowest was 3.76. And the median was 5.93.


Zhejiang Shouxiangu Pharmaceutical Co  (SHSE:603896) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.14/3.46
=4.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Shouxiangu Pharmaceutical Co was 6.79. The lowest was 3.76. And the median was 5.93.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zhejiang Shouxiangu Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Zhejiang Shouxiangu Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Shouxiangu Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Zhejiang Shouxiangu Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.43 3.43

Zhejiang Shouxiangu Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 3.41 3.41 3.43 3.46

SHSE:603896 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Shouxiangu Pharmaceutical Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603896
58GF Score
Zhejiang Shouxiangu Pharmaceutical Co Ltd SHSE:603896
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Shouxiangu Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zhejiang Shouxiangu Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.835/116.3033*116.3033
=0.835

Current CPI (Mar. 2026) = 116.3033.

Zhejiang Shouxiangu Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.462 101.400 0.530
201609 0.431 102.400 0.490
201612 0.786 102.600 0.891
201703 0.655 103.200 0.738
201706 0.516 103.100 0.582
201709 0.423 104.100 0.473
201712 0.761 104.500 0.847
201803 0.699 105.300 0.772
201806 0.532 104.900 0.590
201809 0.524 106.600 0.572
201812 1.043 106.500 1.139
201903 0.911 107.700 0.984
201906 0.476 107.700 0.514
201909 0.482 109.800 0.511
201912 1.152 111.200 1.205
202003 0.716 112.300 0.742
202006 0.532 110.400 0.560
202009 0.852 111.700 0.887
202012 1.335 111.500 1.393
202103 0.910 112.662 0.939
202106 0.763 111.769 0.794
202109 0.807 112.215 0.836
202112 1.556 113.108 1.600
202203 1.036 114.335 1.054
202206 0.752 114.558 0.763
202209 0.823 115.339 0.830
202212 1.654 115.116 1.671
202303 1.054 115.116 1.065
202306 0.841 114.558 0.854
202309 0.871 115.339 0.878
202312 1.245 114.781 1.262
202403 1.117 115.227 1.127
202406 0.692 114.781 0.701
202409 0.612 115.785 0.615
202412 1.133 114.893 1.147
202503 0.870 115.116 0.879
202506 0.635 114.907 0.643
202509 0.687 115.471 0.692
202512 0.953 115.832 0.957
202603 0.835 116.303 0.835

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥3.46 mean?
Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) has a Cyclically Adjusted Revenue per Share of ¥3.46 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Shouxiangu Pharmaceutical Co and its competitors.
Is Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Zhejiang Shouxiangu Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥3.46. Overall, Zhejiang Shouxiangu Pharmaceutical Co has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Zhejiang Shouxiangu Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥3.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Shouxiangu Pharmaceutical Co and its competitors. Zhejiang Shouxiangu Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥3.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shouxiangu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) is currently considered Possible Value Trap. The stock's GF Value™ is ¥23.29, compared to a current price of ¥15.14 — trading 35% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥3.46. Zhejiang Shouxiangu Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896), the current Cyclically Adjusted Revenue per Share is ¥3.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Shouxiangu Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥15.14 is trading 35% below its estimated GF Value™ of ¥23.29. GuruFocus considers Zhejiang Shouxiangu Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for SHSE:603896:

  • Cyclically Adjusted Revenue per Share: ¥3.46
  • GF Value™: ¥23.29 vs. price of ¥15.14 (35% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603896 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Shouxiangu Pharmaceutical Co Business Description

Address 12th Huang Long Road, Wuyi County, Zhejiang Province, Wuyi, CHN, 321200
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a Chinese pharmaceutical company.
58GF Score

Get the complete analysis for SHSE:603896

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.14
Price
¥23.29
GF Value